Navigation Links
NeoStem Provides Update on Amorcyte Clinical Progress and Reports Results for Second Quarter
Date:8/15/2011

ially greater statistical power. A composite of cardiac measures, including clinically meaningful endpoints, will support the primary endpoint of perfusion. "Though the plan was to enroll the first patient early in 2012, we are now confident that we will begin the Phase II program ahead of schedule," said Dr. Pecora.

Dr. Robin Smith, NeoStem CEO, said, "We are thrilled to see Amorcyte advancing through the FDA's drug development process and moving forward with the Phase II clinical trial. We believe that AMR-001 represents a potential breakthrough therapy for a large unmet medical need. We see tremendous potential pharmacoeconomic benefit in this therapy, which we believe could change both the clinical adverse events associated with serious heart attacks and improve a patient's quality of life, all with one therapeutic intervention." 

NeoStem continues its transition to cell based therapeutics and Progenitor Cell Therapy ("PCT's") capabilities in quality cell manufacturing are a key advantage in the development of AMR-001 as well as future cell-based therapeutics candidates the Company may pursue.

NeoStem reported its unaudited results for the three and six months ended June 30, 2011. Revenues for the three and six months ended June 30, 2011 were $18.5 million and $38.1 million compared to $19.4 million and $35.2 million for the same periods in 2010.  Revenues in its Pharmaceutical Manufacturing – China business for the three and six months ended June 30, 2011 reflected lower sales due to a strategic decision by management to discontinue selling certain pharmaceutical intermediates to other pharmaceutical manufacturers, in order to create capacity within the existing production lines for higher margin products in the future.

Net losses attributable to NeoStem's controlling interests for the three and six months ended June 30, 2011 were $10.8 million or $0.13 per share (including $4.6 million of non-cash equity-based compe
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
2. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
3. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
4. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
5. NeoStem Announces Warrant Exercise by Principal Shareholder
6. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
7. NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility
8. NeoStem Adds Distinguished Researcher to its World-Class Scientific Advisory Board
9. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
10. NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement
11. NeoStem to Present at Cell Therapy Industry Summit to be held on November 3-5, 2010 in Carlsbad, California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... The report "Silage Inoculants & ... Pediococcus & Enterococcus), Enzymes (Fibre-digesting & Starch-digesting), Crop-type & ... Inoculants & Enzymes Market is expected to reach $489.05 ... 2015 to 2020. Browse 75 market ... P ages and an in-depth TOC ...
(Date:7/2/2015)... 2. Juli 2015 BGI gab heute ... Hongkong vom American College of Pathologists (CAP) ... das erste klinische Next-Generation-Sequencing Labor, das in ... erhält und somit die höchsten Standards an ... US FDA - 21 CFR Part 11 ...
(Date:7/2/2015)... July 2, 2015  AbbVie (NYSE: ABBV ) ... July 24, 2015, before the market opens. ... conference call at 8 a.m. Central time (9 a.m. ... website at www.abbvieinvestor.com . An archived edition of ... time. About AbbVie AbbVie is ...
Breaking Medicine Technology:Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
... Harnessing Immune System to Fight Tumors, CHICAGO, ... a leading provider of innovative cancer care for ... accepting,patients for an ovarian cancer vaccine clinical trial. ... the U.S. Food and Drug,Administration (FDA), will evaluate ...
... May 22 Roche announced today that a ... oral chemotherapy Xeloda(R),(capecitabine) have been accepted for presentation ... Annual Meeting in Chicago from May 30,to June ... in The 2008 ASCO Proceedings I,compares the preclinical ...
Cached Medicine Technology:Ovarian Cancer Vaccine Clinical Trial Begins at Cancer Treatment Centers of America 2Ovarian Cancer Vaccine Clinical Trial Begins at Cancer Treatment Centers of America 3Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting 2Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting 3
(Date:7/3/2015)... ... July 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Dallas Rhinoplasty Symposium . To be held from March 4th - 6th, the 2016 ... the Westin Galleria Dallas. , Designed to take participants from the basic training and ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... healthcare providers, has been retained to lead a national chief nursing officer ... top-ranked executive search firms in the healthcare industry, B. E. Smith has recently ...
(Date:7/3/2015)... ... 2015 , ... Smoothies are all the rage right now and all you ... ingredients. Aurora Natural is proud to introduce a new line of all natural products ... vitamins and minerals! , Aurora is offering a variety of blends and stand-alone items ...
(Date:7/3/2015)... TX (PRWEB) , ... July 03, 2015 , ... Jennifer ... First Choice Emergency Room , the largest network of independent freestanding emergency rooms ... new facility medical director of our Sienna Plantation facility,” said Executive Medical Director of ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a Stick ” was ... and coolest technology products available to consumers. Amanda Forstrom, a technology expert and special ... are great for documenting memories. , Almost every smartphone has an incredibly powerful camera ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Learn How to Take Selfies like Kendall Jenner 2
... Synovics,Pharmaceuticals, Inc. (OTC Bulletin Board: SYVC), a ... Report,with the Securities and Exchange Commission. Consolidated gross ... 2008 were $6,121,632 compared,to $5,713,761 for the same ... strong growth of the over-the-counter (OTC) product line ...
... based on successful,management of nearly 45,000 cases ... NEWPORT NEWS, Va., June 17 ... organization providing direct,case management services and healthcare ... and chronic diseases each year who are,unable ...
... ,magic bullet, to help miilions of children in ... News) -- A new compound that may lead to ... by researchers at the University of Texas Health Science ... especially important for developing countries, where diarrhea is a ...
... a doctor could get a lot longer if the current ... increase soon, according to a new University of Missouri study. ... the MU School of Medicine, and his research team found ... 44,000 family physicians and general internists in less than 20 ...
... blood tests for breast, ovarian cancers, HERNDON, ... (CIT), a state-chartered non-profit, announced today,that its GAP ... of Funds, made,a $100,000 early-stage investment in OTraces, ... accurate and sensitive blood screening,tests for breast and ...
... in less than 90 seconds ... Varian Medical Systems, DECATUR, Ill., June 17 Decatur ... third in the,United States, to treat a cancer patient using ... John Hosler, an,85-year-old prostate cancer patient, received his treatment in ...
Cached Medicine News:Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 2Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 3Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 4Health News:Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC 5Health News:Patient Data Analysis Report Finds More Than 75 Percent of Chronically Ill Patients Unable to Obtain Needed Healthcare Have Some Form of Insurance 2Health News:Inexpensive Compound Could Treat Severe Diarrhea 2Health News:US could face shortage of 44,000 primary care physicians by 2025 2Health News:US could face shortage of 44,000 primary care physicians by 2025 3Health News:CIT GAP Funds Invests in OTraces, Inc. 2Health News:Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology 2Health News:Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: